Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study

Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study

Bibliographic Details
Main Authors:	Yang Lo, Yu-Huei Huang, Tsen-Fang Tsai
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Dermatologica Sinica
Online Access:	http://www.dermsinica.org/article.asp?issn=1027-8117;year=2021;volume=39;issue=2;spage=87;epage=88;aulast=Lo

Similar Items

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01)

Secukinumab in erythrodermic psoriasis – A promising drug
by: Anwita Sinha, et al.
Published: (2020-01-01)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018-11-01)

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019-01-01)

Updates on the Treatment of Erythrodermic Psoriasis
by: Lo Y, et al.
Published: (2021-06-01)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
by: Susanne Hartz, et al.
Published: (2020-08-01)

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
by: Tzong-Yun Ger, et al.
Published: (2019-04-01)

Erythrodermic psoriasis treated with apremilast
by: John Arcilla, et al.
Published: (2016-09-01)

Treatment of erythrodermic psoriasis with apremilast
by: Olivia A. Gioe, MD, et al.
Published: (2021-05-01)

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab
by: Martin Tichy
Published: (2019-08-01)

Secukinumab in psoriasis
by: Col Manas Chatterjee, et al.
Published: (2019-01-01)

Use of Secukinumab in a Cohort of Erythrodermic Psoriatic Patients: A Pilot Study
by: Giovanni Damiani, et al.
Published: (2019-05-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017-03-01)

The Management of Erythrodermic Psoriasis Complicated by Cyclosporine
by: Suman Rao, et al.
Published: (2020-01-01)

Secukinumab for plaque psoriasis
by: Gonzalo Ordenes-Cavieres, et al.
Published: (2018-11-01)

Respiratory Distress Syndrome Associated with Erythrodermic Psoriasis
by: Lamya Noure, et al.
Published: (2021-02-01)

Low-dose ciclosporin therapy of erythrodermic psoriasis
by: Ryszard Galus, et al.
Published: (2014-07-01)

Erythrodermic psoriasis: pathophysiology and current treatment perspectives
by: Singh RK, et al.
Published: (2016-07-01)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020-03-01)

Ixekizumab May Improve Renal Function in Psoriasis
by: Giuseppe Fabrizio Amoruso, et al.
Published: (2021-05-01)

Secukinumab in generalized pustular psoriasis
by: Shraddha Madanagobalane
Published: (2018-01-01)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019-09-01)

Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy
by: John Ellis, et al.
Published: (2019-01-01)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
by: Sara Ghoneim, et al.
Published: (2017-01-01)

The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.
by: Chen-Yu Wu, et al.
Published: (2019-01-01)

Congenital erythrodermic psoriasis with atopic dermatitis: An example of immunogenetic spinoff
by: K Parimalam, et al.
Published: (2013-01-01)

Infantile erythrodermic psoriasis: A case report and review of the literature
by: Piyush Kumar, et al.
Published: (2017-01-01)

IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience
by: Shany Sherman, et al.
Published: (2019-05-01)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Sekhon S, et al.
Published: (2017-11-01)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017-04-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013-03-01)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020-12-01)

Psoriasis herpeticum due to Varicella zoster virus: A Kaposi′s varicelliform eruption in erythrodermic psoriasis
by: Geeta Garg, et al.
Published: (2012-01-01)

Erythrodermic Psoriasis with Superimposed Fungal Infection-a Presentation in the Emergency Room
by: Muhammad Akbar Baig, et al.
Published: (2018-03-01)

Promising results with secukinumab in refractory pediatric psoriasis
by: Sukriti Baveja, et al.
Published: (2020-01-01)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
by: Yang EJ, et al.
Published: (2018-10-01)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
by: Alessio Gambardella
Published: (2019-09-01)

Profile of secukinumab in the treatment of psoriasis: current perspectives
by: Roman M, et al.
Published: (2015-12-01)